Choosing The Right CDMO In A Multi-Modal CGT Landscape

Our first segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen set the stage for how cell and gene therapy developers are rethinking outsourcing as pipelines expand beyond single modalities, weighing the tradeoffs between using one multimodal CDMO versus multiple specialized partners. Panelists emphasized that while cost and capacity still matter, they are no longer the primary differentiators; instead, technical depth, modality-specific expertise, regulatory and CMC integration, and, above all, timeline reliability drive CDMO selection.